OncoMatch/Clinical Trials/NCT06907043
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Is NCT06907043 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies EIK1004-001 (IMP1707-001) for advanced solid tumors.
Treatment: EIK1004-001 (IMP1707-001) — This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy — neoadjuvant/adjuvant/metastatic
Breast cancer: must have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting
Must have received: hormonal therapy
must have received hormonal therapy if HR+
Must have received: platinum-based chemotherapy — advanced disease
must have received at least one prior platinum-based chemotherapy for advanced disease
Must have received: androgen deprivation therapy — ongoing
mCRPC with ongoing ADT
Must have received: novel hormonal agent
must have received NHA
Must have received: taxane
up to 1 prior line of taxane chemotherapy
Must have received: first-line therapy
Pancreatic cancer, must have prior 1L therapy
Must have received: PARP inhibitor
Up to 1 prior line of PARP inhibitor containing treatment
Cannot have received: PARP1 selective inhibitor
Have received prior PARP1 selective inhibitors
Cannot have received: any investigational or approved anti-cancer therapies
Any investigational or approved anti-cancer therapies administered within 28 days/ before the first dose of EIK1004 (IMP1707)
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Mean resting QTcF > 470 ms or QTcF < 340 ms [excluded]
Adequate organ function; Mean resting QTcF > 470 ms or QTcF < 340 ms [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarah Cannon Research Institute at HealthOne · Denver, Colorado
- Florida Cancer Center · Lake Mary, Florida
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- MD Anderson · Houston, Texas
- NEXT Oncology · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify